EA201491734A1 - Стабилизированные фармацевтические композиции, содержащие соли разагилина - Google Patents

Стабилизированные фармацевтические композиции, содержащие соли разагилина

Info

Publication number
EA201491734A1
EA201491734A1 EA201491734A EA201491734A EA201491734A1 EA 201491734 A1 EA201491734 A1 EA 201491734A1 EA 201491734 A EA201491734 A EA 201491734A EA 201491734 A EA201491734 A EA 201491734A EA 201491734 A1 EA201491734 A1 EA 201491734A1
Authority
EA
Eurasian Patent Office
Prior art keywords
salts
pharmaceutical compositions
razagilina
compositions containing
stabilized pharmaceutical
Prior art date
Application number
EA201491734A
Other languages
English (en)
Inventor
Лисардо Альварес Фернандес
Вальтер Вильхельмус Йоханнес Элффринк
Original Assignee
Синтон Бв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Синтон Бв filed Critical Синтон Бв
Publication of EA201491734A1 publication Critical patent/EA201491734A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение рассматривает способы получения стабильных твердых фармацевтических композиций с однородным содержанием, содержащих соли разагилина и L-винной или фумаровой кислоты в качестве активного ингредиента. Результат данного способа представляет собой стабильную фармацевтическую композицию с однородным содержанием, содержащую L-тартрат или фумарат разагилина и L-винную кислоту.
EA201491734A 2012-03-21 2012-03-21 Стабилизированные фармацевтические композиции, содержащие соли разагилина EA201491734A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/054973 WO2013139387A1 (en) 2012-03-21 2012-03-21 Stabilized pharmaceutical compositions comprising rasagiline salts

Publications (1)

Publication Number Publication Date
EA201491734A1 true EA201491734A1 (ru) 2015-01-30

Family

ID=45932304

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491734A EA201491734A1 (ru) 2012-03-21 2012-03-21 Стабилизированные фармацевтические композиции, содержащие соли разагилина

Country Status (5)

Country Link
EP (1) EP2827848B1 (ru)
EA (1) EA201491734A1 (ru)
ES (1) ES2584059T3 (ru)
MX (1) MX343986B (ru)
WO (1) WO2013139387A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524865T1 (es) * 2013-02-06 2014-12-15 Galenicum Health S.L. Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
WO2015086768A1 (en) * 2013-12-11 2015-06-18 Krka, D.D., Novo Mesto Pharmaceutical composition comprising a pharmaceutically acceptable salt of rasagiline

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL141690A (en) * 2001-02-27 2004-06-20 Isp Finetech Ltd Process for preparation of rasagiline and its salts
CA2588293C (en) 2004-11-24 2013-07-02 Teva Pharmaceutical Industries Ltd. Rasagiline orally disintegrating compositions
BRPI0608209A2 (pt) 2005-02-23 2010-11-09 Teva Pharma mistura de partìculas, composição sólida, método para tratamento de um paciente com mal de parkinson, processo para preparação de uma composição, e, composição farmacêutica sólida
WO2007061717A2 (en) 2005-11-17 2007-05-31 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
ZA200903903B (en) 2006-12-14 2010-08-25 Teva Pharma Crystalline solid rasagiline base
EP2101570B1 (en) 2006-12-14 2013-02-13 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
WO2009118657A2 (en) 2008-03-28 2009-10-01 Medichem, S.A. Polymorphic form of an aminoindan mesylate derivative
US20110117200A1 (en) 2008-03-31 2011-05-19 Actavis Group Ptc Ehf Rasagiline mesylate particles and process for the preparation thereof
EP2303829A2 (en) 2008-05-23 2011-04-06 Medichem, S.A. A new method for obtaining an aminoindan mesylate derivative
NZ589547A (en) 2008-06-19 2013-03-28 Teva Pharma Dried rasagiline base having a water content less than 0.5 % by weight
WO2011012140A2 (en) 2008-07-11 2011-02-03 Synthon Bv Polymorphs of rasagiline hydrochloride
AR074637A1 (es) 2008-07-18 2011-02-02 Medichem Sa Formas de sal de adicion acida de r-(+)-n-propargil-1-aminoindano (es decir , base de rasagilina), un compuesto de formula (1), procesos para prepararlos y aislarlos y usos de los mismos
US20100029987A1 (en) 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
WO2010013048A1 (en) 2008-07-30 2010-02-04 Generics [Uk] Limited Polymorphic form of rasagiline mesylate
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan

Also Published As

Publication number Publication date
EP2827848A1 (en) 2015-01-28
WO2013139387A1 (en) 2013-09-26
MX343986B (es) 2016-12-01
EP2827848B1 (en) 2016-04-27
ES2584059T3 (es) 2016-09-23
MX2014010208A (es) 2014-11-21

Similar Documents

Publication Publication Date Title
CY1121843T1 (el) Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου
MX2017008136A (es) Sal de l-tartrato de pridopidina.
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
EA201391087A1 (ru) Оральные лекарственные формы препарата тазоцитиниба с модифицированным высвобождением
JO3454B1 (ar) تركيبات وطرق لتعديل مستقبلات فارنيسويد x
EA201692104A1 (ru) Ингибиторы асс и их применения
EA201391318A1 (ru) Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение
EP3949973A3 (en) Compositions and methods for treating depression
CL2012003681A1 (es) Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes.
EA201490756A1 (ru) Разагилина цитрамид
EA201691881A1 (ru) Новые соединения
PH12018501644A1 (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
EA201490152A1 (ru) Антагонисты trpm8 и их применение при лечении
EA201391481A1 (ru) Аналоги эпоксиэйкозатриеновой кислоты и способы их получения и использования
EA201691538A1 (ru) Способ получения солей вортиоксетина
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
EA201400210A1 (ru) Применение и агрохимическая композиция дибутиламидов карбоновой кислоты
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201491734A1 (ru) Стабилизированные фармацевтические композиции, содержащие соли разагилина
EA201590853A1 (ru) Твердая солевая форма альфа-6-mpeg6-o-гидроксикодона в качестве опиоидных агонистов и ее применения
UA110822C2 (uk) Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів
MX2013007578A (es) Combinacionfarmaceutica fitoterapeutica de lippia salviifolia y lippia sidoides, composicion farmaceutica fitoterapeutica, proceso para preparar una composicion farmaceutica fitoterapeutica y sus usos veterinarios.
TR201009166A2 (tr) Sefdinir içeren farmasötik bileşim için üretim yöntemi